 WILMINGTON, Del., Jan. 11, 2021 GLOBE NEWSWIRE -- Prelude Therapeutics Incorporated Prelude or the Company Nasdaq: PRLD, a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of 60.00 per share, which includes the exercise in full of the underwriters option to purchase an additional 375,000 shares of its voting common stock. The aggregate gross proceeds from this offering were 172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude. 